Lonza

Moderna COVID-19 Vaccine Partner Lonza Certain Of Starting Commercial Production This Year

Lonza said Tuesday the plants it's building to manufacture Moderna Inc’s (NASDAQ: MRNA) COVID-19 vaccine in the United States and Switzerland will be ready this year, Reuters reported.

Moderna, Lonza Strike Deal To Manufacture Coronavirus Vaccine Candidate

Moderna Inc's (NASDAQ: MRNA) novel coronavirus vaccine program is brimming with activity, and the latest news out of the stable Friday is a 10-year strategic collaboration deal with Lonza, a Swiss contract development and manufacturing organization.